The use of sequential single-gene testing to detect genomic alterations in metastatic non-small cell lung cancer (NSCLC) can be costly, particularly with new mutations to test for being added as our knowledge of this disease expands. Here, Nathan Pennell, MD, PhD, of the Cleveland Clinic, Cleveland, OH, discusses the economic impact of next-generation sequencing (NGS) in this setting compared with exclusionary testing or hotspot panels. Prof. Pennell highlights the cost- and time-saving nature of NGS. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
Economic impact of NGS for NSCLC diagnostics
